前列腺癌组学分子分型、预后预测及个性化治疗的研究进展  

Omics molecular subtyping,prognostic prediction and individualized treatment of prostate cancer:Advances in studies

作　　者：葛秦涛 孟佳林[1,2,3] 梁朝朝 GE Qin-tao;MENG Jia-lin;LIANG Chao-zhao(Department of Urology,The First Affiliated Hospital of Anhui Medical University,Anhui Medical University,Hefei,Anhui 230022,China;Research Institute of Urology,Anhui Medical University,Anhui Medical University,Hefei,Anhui 230022,China;Key Laboratory of Anhui Province for Genitourinary Diseases,Anhui Medical University,Hefei,Anhui 230022,China)

机构地区：[1]安徽医科大学第一附属医院泌尿外科,安徽合肥230022 [2]安徽医科大学泌尿外科研究所,安徽合肥230022 [3]泌尿生殖系统疾病安徽省重点实验室,安徽合肥230022

出　　处：《中华男科学杂志》2022年第9期837-842,共6页National Journal of Andrology

基　　金：安徽省中央引导地方科技发展项目-安徽省泌尿外科临床医学中心(2019b07030004)。

摘　　要：前列腺癌(PCa)是男性最常见的癌症,相比于其他癌症,具有较大的异质性,这给其临床诊断、分型以及预后监测都带来了巨大的挑战。目前临床上主要采用Gleason评分结合前列腺特异性抗原水平来区分高、中、低危肿瘤,但是未能从本质上揭示PCa的差异,不能精确地区分出不同类型的PCa。随着高通量测序的发展,越来越多的研究开始从分子层面对PCa进行分类,这为PCa的早期诊断、疗效预测和个体化治疗方案的筛选提供了基础。本文就现阶段PCa组学分子分型、预后预测以及个性化治疗等方面进行回顾,旨在为PCa精准医疗的发展提供启示。Prostate cancer(PCa)is a most common malignancy in males.It has a greater heterogeneity than other cancers,which poses a real challenge to the clinical diagnosis,classification and prognostic monitoring.At present,high-,medium-and low-risk PCa patients are classified mainly by Gleason scores and the PSA level,which,however,fail to reveal the diverse molecular heterogeneity and precisely distinguish the molecular subtypes of PCa.With the development of high-throughput sequencing,more and more studies on the molecular classification of the malignancy have paved the theoretical ground for the early diagnosis,efficacy prediction and individualized treatment of PCa.This study reviews the molecular classification,prognosis prediction and individualized treatment of PCa to date,hoping to contribute to the development of the precise treatment of PCa.

关 键 词：前列腺癌 分子分型 精准医疗 预后 

分 类 号：R737.25[医药卫生—肿瘤]